2026-04-13T04:15:02Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/116682025-10-24T02:03:19Zcom_2072_378070com_2072_378040col_2072_378092

urn:hdl:11351/11668 BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC Robado de Lope, Lucía Serna-Blasco, Roberto Diz Tain, Pilar provencio, mariano Nadal, Ernest Massuti, Bartomeu MARTINEZ-MARTI, ALEX Avaluació de resultats (Assistència sanitària) Anomalies cromosòmiques Pulmons - Càncer - Immunoteràpia Pulmons - Càncer - Aspectes genètics PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung Other subheadings::Other subheadings::Other subheadings::/drug therapy ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome::Progression-Free Survival FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento::supervivencia libre de progresión BRAF; Immunotherapy; NSCLC BRAF; Immunoteràpia; NSCLC BRAF; Inmunoterapia; NSCLC Background Immunotherapy-based treatments have demonstrated high efficacy in patients with advanced and locally advanced non-small-cell lung cancer (NSCLC). BRAF mutations affect a small but significant fraction of NSCLC. The efficacy of these therapies in this subgroup of patients is unknown. Materials and methods Plasma and tissue samples from 116 resectable stage IIIA/B NSCLC patients, included in NADIM and NADIM II clinical trials (NADIM cohort), and from a prospective academic cohort with 84 stage IV NSCLC patients (BLI-O cohort), were analyzed by next-generation sequencing. Results The p.G464E, p.G466R, p.G466V, p.G469V, p.L597Q, p.T599I, p.V600E (n = 2) BRAF mutations, were identified in four (3.45 %) samples from the NADIM cohort, all of which were cases treated with neoadjuvant chemoimmunotherapy (CH-IO), and four (4.76 %) samples from the BLI-O cohort, corresponding to cases treated with first-line immunotherapy (n = 2) or CH-IO (n = 2). All these patients were alive and had no evidence of disease at data cut-off. Conversely, patients with BRAF wild-type (wt) tumors in the BLI-O cohort had a median progression-free survival (PFS) of 5.49 months and a median overall survival (OS) of 12.00 months (P-LogRank = 0.013 and 0.046, respectively). Likewise, PFS and OS probabilities at 36 months were 60.5 % and 76.1 % for patients with BRAF-wt tumors in the NADIM cohort. The pathological complete response (pCR) rate after neoadjuvant CH-IO in patients with BRAF-positive tumors (n = 4) was 100 %, whereas the pCR rate in the BRAF-wt population was 44.3 % (RR: 2.26; 95 % CI: 1.78–2.85; P < 0.001). Conclusion BRAF mutations may be a good prognostic factor for advanced and locally advanced NSCLC patients undergoing immunotherapy-based treatments. This study was funded by Bristol-Myers Squibb. The study was also supported by the European Union Horizon 2020 Research and Innovation program (European Commission) under grant agreement no. 875160. In addition, the project received funds from Instituto de Salud Carlos III (ISCIII) PI19/01652, PI21/01500 (Co-funded by European Regional Development Fund/ European Social Fund ‘A way to make Europe’/‘Investing in your future’ from European Commission) and grant RTC2019-007359–1 (BLI- O) from the Ministry of Science and Innovation. A.C-B. is supported by Sara Borrell fellowship grant n°CD19/00170. Instituto de Salud Carlos III (ISCIII). L R dL is supported by grant JDC2022-049091-I The Spanish State Research Agency. 2024-07-04T12:07:20Z 2024-07-04T12:07:20Z 2024-06-26 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Lung Cancer;194 https://doi.org/10.1016/j.lungcan.2024.107865 info:eu-repo/grantAgreement/EC/H2020/875160 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Elsevier Scientia